Abstract

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FRα binding domain is fully human, thereby preventing a host immune response.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/725 - T-cell receptors

Abstract

New antibodies are described having high specificity to the a-folate receptor, being of medical interest in the therapy of tumours and of other discases involving an increased expression of the a-folate receptor. All the antibodies of the present invention share the same six specific CDR in the VH and VL regions, herein defined by SEQ. ID. Nos: 1-6, responsible for the α-folate receptor specificity. In one embodiment, a subgroup of these antibodies identified as A-type is further characterized by an extended duration of binding to the a-folate receptor and, in an additional embodiment, another subgroup involving some aminoacidic modifications and identified as B-type is also characterized by an increased compatibility for human therapy.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

There is described a protective device (1) for monorenal subjects or subjects with renal disease, comprising : - a garment (2) wearable by a subject (P) at least at a lumbar region (L) of the subject (P), - at least one protective element (4) installed on said garment (2) at a portion thereof configured to be positioned at the lumbar region (L) of the subject (P) when the garment (2) is worn by the subject (P), - a belt element (6) configured to at least partially encircle the torso of the subject (P) in the lumbar region (L) and to exert a compressive action of the at least one protective element (4) against the lumbar region (L) of the subject (P).

IPC Classes  ?

• A41D 13/05 - Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
• A41D 13/12 - Surgeons' or patients' gowns or dresses
• A41D 13/015 - Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches with shock-absorbing means
• A41B 9/12 - Protective undergarments

Abstract

The present invention concerns the field of cancer and methods for early detection of cancerous lesions. Specifically, the invention relates to a method for early detection of cancerous lesions through the analysis of microsatellite instability in the genome of an individual from a liquid biopsy.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention concerns the field of oncology, and in particular tumor diagnosis for specific and tailored therapy. In particular the invention describes a method for diagnosing a tumor in a subject, said method comprising the step of performing an in vitro immunohistochemical (IHC) analysis, wherein said IHC is carried out on a fresh frozen sample and with a specific set of antibodies. The present invention further relates to a kit for IHC analysis comprising the specific panel of antibodies and instructions for use in the method of according to the invention. In a further aspect, the invention relates to the use of a kit for providing a tumor diagnosis, wherein said tumor is chosen from the group consisting of breast, liver, testis, prostate, skin (melanoma), lung, thyroid, colon, colorectal, uterus, lymph node, bladder, pancreas, spleen, upper aerodigestive tract and stomach.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

Daily food preparation for use as a therapeutic adjuvant in the diet of patients suffering from neoplasia, including A) a nutritional combination that contains between 6% and 56% Kcal as carbohydrates, from 7% to 20% Kcal as proteins, from 30% to 86% Kcal as lipids; and B) dietary fiber in an amount between 1 and 30 g, the daily food preparation being characterized by an average caloric content between 199 and 630 Kcal, in which the nutritional combination (A) and the dietary fiber (B) consist of foods of vegetable origin. A further object of the present invention is a kit comprising daily food preparations in accordance with the invention for use as a therapeutic adjuvant in the daily diet of patients suffering from neoplasia.

IPC Classes  ?

• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/115 - Fatty acids or derivatives thereofFats or oils
• A23L 33/185 - Vegetable proteins
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres

Abstract

Method for the control of hypnotic and analgesic concentrations of an anaesthetic composition comprising the steps of: —supplying a memory unit configured to receive and record data; —supplying at least one data processing unit 101, in signal communication with the memory unit and configured to process and record data in the memory unit; —providing the bispectral index (PBIS) and the mean arterial pressure (PMAP) of a patient treated with a first anaesthetic composition comprising an initial hypnotic concentration and an initial analgesic concentration, and storing the patients PBIS and PMAP data in said memory unit; the method being characterized in that it comprises the steps of—providing a two-dimensional matrix defined, on the abscissa, by a MAP dimension relative to the variation of Mean Arterial Pressure, on the ordinate, by a BIS dimension relative to the variation of the Bispectral Index; —defining in the matrix an optimal anaesthesia zone (OAZ) located between MAP values of 65 and 110 mmHg and BIS values of 40 and 60; —localizing in the matrix the values of the PBIS and PMAP data, to define a position of the patient (B) in the matrix with respect to the optimal anaesthesia zone (OAZ); —providing an algorithm resident in said processing unit, configured to quantify the deviation of the patients position (B) with respect to the optimal anaesthesia zone (OAZ) and transforming the deviation into a quantitative variation of the initial hypnotic concentration and/or the initial analgesic concentration of the first anaesthetic composition to define a target hypnotic concentration and/or a target analgesic concentration of a second anaesthetic composition; —processing the patients PBIS and PMAP data using said algorithm to obtain the target hypnotic concentration and/or the target anaesthetic concentration of the second anaesthetic composition.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Abstract

HLL regions, herein defined by SEQ.ID.Nos: 1-6, responsible for the α-folate receptor specificity. In one embodiment, a subgroup of these antibodies identified as A-type is further characterized by an extended duration of binding to the α-folate receptor and, in an additional embodiment, another subgroup involving some aminoacidic modifications and identified as B-type is also characterized by an increased compatibility for human therapy.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention concerns the field of oncology, and in particular tumor diagnosis for specific and tailored therapy. In particular the invention describes a method for diagnosing a tumor in a subject, said method comprising the step of performing an in vitro immunohistochemical (IHC) analysis, wherein said IHC is carried out on a fresh frozen sample and with a specific set of antibodies. The present invention further relates to a kit for IHC analysis comprising the specific panel of antibodies and instructions for use in the method of according to the invention. In a further aspect, the invention relates to the use of a kit for providing a tumor diagnosis, wherein said tumor is chosen from the group consisting of breast, liver, testis, prostate, skin (melanoma), lung, thyroid, colon, colorectal, uterus, lymph node, bladder, pancreas, spleen, upper aerodigestive tract and stomach.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/532 - Production of labelled immunochemicals
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

Daily food preparation for use as a therapeutic adjuvant in the diet of patients suffering from neoplasia, including A) a nutritional combination that contains carbohydrates in an amount between 8% and 55% (w/w), proteins in an amount between 7% and 16% (w/w), lipids in an amount between 30% and 81% (w/w); and B) dietary fiber in an amount between 2 and 30 g, the food preparation being characterized by an average caloric content between 15 and 600 Kcal, in which the nutritional combination (A) and the dietary fiber (B) consist of foods of vegetable origin. A further object of the present invention is a kit comprising daily food preparations in accordance with claim 1 for use as a therapeutic adjuvant in the daily diet of patients suffering from neoplasias.

IPC Classes  ?

• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
• A23L 33/185 - Vegetable proteins
• A23L 33/115 - Fatty acids or derivatives thereofFats or oils

Abstract

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/725 - T-cell receptors

Abstract

Extracellular vesicles isolated from blood plasma of oncological patients for selectively delivering therapeutic or diagnostic drugs are provided. Methods for isolating extracellular vesicles from an isolated sample of blood plasma and for preparing an isolated sample of blood plasma from oncological patients are also provided.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 49/00 - Preparations for testing in vivo
• C12N 5/078 - Cells from blood or from the immune system

Abstract

Daily food preparation for use as a therapeutic adjuvant in the diet of patients suffering from neoplasia, including A) a nutritional combination that contains between 6% and 56% Kcal as carbohydrates, from 7% to 20% Kcal as proteins, from 30% to 86% Kcal as lipids; and B) dietary fiber in an amount between 1 and 30 g, the daily food preparation being characterized by an average caloric content between 199 and 630 Kcal, in which the nutritional combination (A) and the dietary fiber (B) consist of foods of vegetable origin. A further object of the present invention is a kit comprising daily food preparations in accordance with the invention for use as a therapeutic adjuvant in the daily diet of patients suffering from neoplasia.

IPC Classes  ?

• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/185 - Vegetable proteins
• A23L 33/20 - Reducing nutritive valueDietetic products with reduced nutritive value
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators

Abstract

Daily food preparation for use as a therapeutic adjuvant in the diet of patients suffering from neoplasia, including A) a nutritional combination that contains between 6% and 56% Kcal as carbohydrates, from 7% to 20% Kcal as proteins, from 30% to 86% Kcal as lipids; and B) dietary fiber in an amount between 1 and 30 g, the daily food preparation being characterized by an average caloric content between 199 and 630 Kcal, in which the nutritional combination (A) and the dietary fiber (B) consist of foods of vegetable origin. A further object of the present invention is a kit comprising daily food preparations in accordance with the invention for use as a therapeutic adjuvant in the daily diet of patients suffering from neoplasia.

IPC Classes  ?

• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/185 - Vegetable proteins
• A23L 33/20 - Reducing nutritive valueDietetic products with reduced nutritive value
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators

Abstract

Described herein is a method and apparatus for storing a sample of human breath, which includes a metering device having an inlet port and a delivery port; a dispenser device in fluid communication with the delivery port of the metering device; a supply unit configured for delivering a flow of fluid through a delivery port of its own; an acquisition port configured for intake of a sample of human breath; and a selection valve. The selection valve includes a first operating condition, in which a fluid communication is obtained between the acquisition port and the inlet port of the metering device, and a second operating condition, in which a fluid communication is obtained between the delivery port of the supply unit and said metering device.

IPC Classes  ?

• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath
• A61B 5/097 - Devices for facilitating collection of breath or for directing breath into or through measuring devices
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

The present patent application relates to a lyophilisation process of Annatto Bixa Orellana L. powder having a tocotrienol content > 35% (w/w), comprising a pre- freezing step and a freeze-drying step, in which the Annatto powder resulting from the freeze-drying step (c) has a tocotrienol content > 39% (w/w). The invention also relates to pharmaceutical compositions comprising lyophilised Annatto powder obtained with the process of the invention and therapeutic uses of such compositions, in particular to support cancer therapy.

IPC Classes  ?

• A23L 3/44 - Freeze-drying
• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61P 35/00 - Antineoplastic agents

Goods & Services

Printed matter; Book covers; Photographs [printed]; Paper stationery; Gums [adhesives] for stationery or household purposes; Teaching materials [except apparatus]; Plastic materials for packaging (not included in other classes); Printing fonts; Printing blocks; Brochures; Calendars; Electrocardiograph paper and X-ray paper; Briefcases; Catalogues; File folders; Newspapers; Instruction material of teaching (except apparatuses); Books; Manuals [handbooks]; Pencils; Forms, printed; Pamphlets; Picture postcards; Journals, Printed publications, Writing or drawing books, Magazines [periodicals], Bookmarkers, Printed matter. Hospital management; Development of hospital management systems; Advertising; Arranging events for promotional and/or advertisingpurposes. Instruction courses relating to health; Healthcare education; Training services for medical visitors; Education, providing of training, entertainment, sporting and cultural activities; Development of the mental faculties of individuals, and services to entertain or occupy the attention; Presentation of cultural or educational works to the public. Scientific and technological services and scientific research for medical purposes and design relating thereto; Scientific and industrial analysis and research services; biological testing and research; Information technology services for the pharmaceutical and healthcare industries; Food sanitation consultation; Scientific, medical and pharmacological research; Providing information relating to scientific and medical research in the fields of biochemistry, biotechnology, pharmaceutical preparations and clinical testing; DNA screening for scientific research purposes; Advisory services relating to scientific research; Preparation of reports in relation to scientific consultancy. Healthcare, medical and hospital services; Medical analysis relating to the care of persons; Medical services, Health screening, Medical services, Health care in the nature of health maintenance organizations; Consultancy and information in relation to health care and pharmacy; Preparation of reports relating to health care matters, Technical consultancy services relating to medical health; Rehabilitation linked to developing and/or regaining of mental faculties, treatment aimed at stimulating attention; Nursing home services and Rehabilitation centres. Personal and social services rendered by hospitals and others to meet the needs of individuals.

Goods & Services

Printed matter; Book covers; Photographs [printed]; Paper stationery; Gums [adhesives] for stationery or household purposes; Teaching materials [except apparatus]; Plastic materials for packaging (not included in other classes); Printing fonts; Printing blocks; Brochures; Calendars; Electrocardiograph paper and X-ray paper; Briefcases; Catalogues; File folders; Newspapers; Instruction material of teaching (except apparatuses); Books; Manuals [handbooks]; Pencils; Forms, printed; Pamphlets; Picture postcards; Journals, Printed publications, Writing or drawing books, Magazines [periodicals], Bookmarkers, Printed matter. Hospital management; Development of hospital management systems; Advertising; Arranging events for promotional and/or advertisingpurposes. Instruction courses relating to health; Healthcare education; Training services for medical visitors; Education, providing of training, entertainment, sporting and cultural activities; Development of the mental faculties of individuals, and services to entertain or occupy the attention; Presentation of cultural or educational works to the public. Scientific and technological services and scientific research for medical purposes and design relating thereto; Scientific and industrial analysis and research services; biological testing and research; Information technology services for the pharmaceutical and healthcare industries; Food sanitation consultation; Scientific, medical and pharmacological research; Providing information relating to scientific and medical research in the fields of biochemistry, biotechnology, pharmaceutical preparations and clinical testing; DNA screening for scientific research purposes; Advisory services relating to scientific research; Preparation of reports in relation to scientific consultancy. Healthcare, medical and hospital services; Medical analysis relating to the care of persons; Medical services, Health screening, Medical services, Health care in the nature of health maintenance organizations; Consultancy and information in relation to health care and pharmacy; Preparation of reports relating to health care matters, Technical consultancy services relating to medical health; Rehabilitation linked to developing and/or regaining of mental faculties, treatment aimed at stimulating attention; Nursing home services and Rehabilitation centres. Personal and social services rendered by hospitals and others to meet the needs of individuals.

Abstract

BISMAPBISMAPBISMAPBISMAPMAP data using said algorithm to obtain the target hypnotic concentration and/or the target anaesthetic concentration of the second anaesthetic composition.

IPC Classes  ?

• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention relates to magnetic nanoparticles based on iron oxide having cubic shape, suitably functionalized for the release of targeting chemotherapeutic agents, i.e. selectively in the tumors being treated The invention also relates to the pharmaceutical compositions having such nanoparticles and to their use in combined oncological therapies of hyperthermia and chemotherapy, useful in particular in the treatment of ovarian tumors.

IPC Classes  ?

• A61K 33/243 - PlatinumCompounds thereof
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/52 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FRα binding domain is fully human, thereby preventing a host immune response.

IPC Classes  ?

• C07K 16/46 - Hybrid immunoglobulins
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Daily food preparation for use as a therapeutic adjuvant in the diet of patients suffering from neoplasia, including A) a nutritional combination that contains carbohydrates in an amount between 8% and 55% (w/w), proteins in an amount between 7% and 16 % (w/w), lipids in an amount between 30% and 81% (w/w); and B) dietary fiber in an amount between 2 and 30 g, the food preparation being characterized by an average caloric content between 15 and 600 Kcal, in which the nutritional combination (A) and the dietary fiber (B) consist of foods of vegetable origin. A further object of the present invention is a kit comprising daily food preparations in accordance with claim 1 for use as a therapeutic adjuvant in the daily diet of patients suffering from neoplasias.

IPC Classes  ?

• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/115 - Fatty acids or derivatives thereofFats or oils
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/17 - Amino acids, peptides or proteins
• A23L 33/20 - Reducing nutritive valueDietetic products with reduced nutritive value
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
• A61P 35/00 - Antineoplastic agents

Abstract

Daily food preparation for use as a therapeutic adjuvant in the diet of patients suffering from neoplasia, including A) a nutritional combination that contains carbohydrates in an amount between 8% and 55% (w/w), proteins in an amount between 7% and 16 % (w/w), lipids in an amount between 30% and 81% (w/w); and B) dietary fiber in an amount between 2 and 30 g, the food preparation being characterized by an average caloric content between 15 and 600 Kcal, in which the nutritional combination (A) and the dietary fiber (B) consist of foods of vegetable origin. A further object of the present invention is a kit comprising daily food preparations in accordance with claim 1 for use as a therapeutic adjuvant in the daily diet of patients suffering from neoplasias.

IPC Classes  ?

• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A61P 35/00 - Antineoplastic agents

Abstract

This invention relates to the use of extracellular vesicles isolated from the plasma of oncological patients for selectively delivering therapeutic or diagnostic drugs.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents

Abstract

This invention relates to the use of extracellular vesicles isolated from the plasma of oncological patients for selectively delivering therapeutic or diagnostic drugs.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/725 - T-cell receptors
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells

Abstract

Described herein is an apparatus (1; 1*; 1**; 100; 100*) for storing a sample of human breath, which comprises: a metering device (2) having an inlet port (3) and a delivery port (4); a dispenser device (5) in fluid communication with the delivery port (4) of the metering device (2); a supply unit (6) configured for delivering a flow of fluid through a delivery port (7) of its own; an acquisition port (8) configured for intake of a sample of human breath; and a selection valve (9; 9**). The selection valve (9; 9**) includes a first operating condition (9A), in which a fluid communication is obtained between the acquisition port (8) and the inlet port (3) of the metering device (2), and a second operating condition (9B; 9B**), in which a fluid communication is obtained between the delivery port (7) of the supply unit (6) and said metering device (2).

IPC Classes  ?

• A61B 5/097 - Devices for facilitating collection of breath or for directing breath into or through measuring devices
• A61B 5/08 - Measuring devices for evaluating the respiratory organs
• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes
• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

The present invention relates to magnetic nanoparticles based on iron oxide having cubic shape, suitably functionalized for the release of targeting chemotherapeutic agents, i.e. selectively in the tumors being treated; the invention also relates to the pharmaceutical compositions comprising such nanoparticles and to their use in combined oncological therapies of hyperthermia and chemotherapy, useful in particular in the treatment of ovarian tumors.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention concerns the field of cancer immunotherapy, and in particular drugs with low toxicity which can overcome drug-resistance. The present invention concerns novel bispecific antibodies which have the capability of binding both the TRAIL tumor associated antigen and the T lymphocyte CD3. The invention further relates to compositions comprising the bispecific antibodies and a labelling agent, and to pharmaceutical compositions. The present invention also relates to the use of the bispecific antibodies in the treatment of a tumor.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FRα binding domain is fully human, thereby preventing a host immune response.

IPC Classes  ?

• C07K 16/46 - Hybrid immunoglobulins
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/725 - T-cell receptors

Abstract

The present invention concerns the field of cancer immunotherapy, and in particular drugs with low toxicity which can overcome drug-resistance. The present invention concerns novel bispecific antibodies which have the capability of binding both the TRAIL tumor associated antigen and the T lymphocyte CD3. The invention further relates to compositions comprising the bispecific antibodies and a labelling agent, and to pharmaceutical compositions. The present invention also relates to the use of the bispecific antibodies in the treatment of a tumor.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 14/725 - T-cell receptors
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells

Abstract

The present invention concerns the field of cancer immunotherapy, and in particular drugs with low toxicity which can overcome drug-resistance. The present invention concerns novel bispecific antibodies which have the capability of binding both the TRAIL tumor associated antigen and the T lymphocyte CD3. The invention further relates to compositions comprising the bispecific antibodies and a labelling agent, and to pharmaceutical compositions. The present invention also relates to the use of the bispecific antibodies in the treatment of a tumor.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present invention relates to the interaction between JMJD6 protein and collagen and to the possibility of inhibiting this interaction for the prevention and treatment of fibrosis and of tumor metastases. The invention further relates to a compound that is able to block the interaction between collagen and JMJD6 protein, in particular the invention relates to a new monoclonal antibody that recognizes JMJD6 and is able to block this interaction.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a compound having formula (I) below or a pharmaceutically acceptable salt thereof: wherein: X is -COOH or NH2; R is a straight or branched C1-C10 alkylene chain; and R1 is H, straight or branched C1-C10 alkyl, aryl, or R2CO- wherein R2 is straight or branched C1-C10 alkyl, for use as antitumoral agents.

IPC Classes  ?

• C07C 251/60 - Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by carboxyl groups
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol

Abstract

The present invention relates to a compound having formula (I) below or a pharmaceutically acceptable salt thereof: wherein: X is -COOH or NH2; R is a straight or branched C1-C10 alkylene chain; and R1 is H, straight or branched C1-C10 alkyl, aryl, or R2CO- wherein R2 is straight or branched C1-C10 alkyl, for use as antitumoral agents.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• C07C 251/60 - Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by carboxyl groups

Abstract

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having alpha-folate receptor (FR-alpha) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FR-alpha binding domain is fully human, thereby preventing a host immune response.

IPC Classes  ?

• A01N 63/00 - Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
• C12N 5/07 - Animal cells or tissues
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12P 21/04 - Cyclic or bridged peptides or polypeptides, e.g. bacitracin
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C07K 1/00 - General processes for the preparation of peptides
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Disclosed herein are methods for detecting in a biological sample from a patient the presence or absence of a fusion gene having a 5' portion from a fibroblast growth factor receptor 2 (FGFR2) gene or fragment thereof and a 3' portion from a Periphilin-1 (PPHLN1) gene or fragment thereof. The methods can further include diagnosing and treating the patient for intrahepatic cholangiocarcinoma.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

IPC Classes  ?

• A61K 35/14 - BloodArtificial blood
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.

IPC Classes  ?

• C07K 5/083 - Tripeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
• C07D 487/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam

Abstract

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having a-folate receptor (FRa) binding domain and 4- IBB (CD137) costimulatory domain to treat ovarian cancer.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 19/00 - Hybrid peptides
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

The invention provides compositions and methods for treating ovarian cancer.Specifically, the invention relates to administering a genetically modified T cell having a-folatereceptor (FRO binding domain and 4- IBB (CD137) costimulatory domain to treat ovariancancer.

IPC Classes  ?

• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• A61P 37/04 - Immunostimulants
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 19/00 - Hybrid peptides
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

A medical composition including a chemotherapeutic medication or a targeted therapy medication is used in a human female patient for the treatment of a disease selected in the group comprising cervical cancer, cervical intraepithelial neoplasia (CIN), human papillomavirus (HPV) infection of the female genital system; the chemotherapeutic agent or targeted therapy medication is locally delivered directly to cervix of a female genital system by an implanted medical device including a stem to be implanted in the cervix. The stem has a drug carrying layer including the medical composition. A process for the treatment of the above diseases is also disclosed.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Abstract

A multi-kinase inhibitor, in particular Sorafenib, is used for the preparation of a pharmaceutical composition in the treatment of a variety o pathological conditions involving vascular hyperpermeability in order to reduce vascular hyperpermeability.

IPC Classes  ?

• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 7/10 - Antioedematous agentsDiuretics

Abstract

An isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen (PSMA) preferably in its native form on the surface of tumour cells. A conjugate of the antibody with an active ingredient and modified forms of the antigen-binding antibody fragment are also provided. The complete antibody and the antigen- recognising fragment thereof are used alone or conjugated for the treatment and the diagnosis of tumours or tissues associated to the tumour overexpressing the PSMA antigen, preferably prostatic neoplastic diseases.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The present invention relates to compounds conformationally constrained mimetics of Smac with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs), the invention also relates to the use of these compounds in therapy, wherein the induction of apoptotic cell death is beneficial, especially in the treatment of cancer, alone or in combination with other active ingredients.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy.

IPC Classes  ?

• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer